PA-U7 (Anthrax Protective Mutant Antigen (PA-U7))

Protective antigen (PA) mutant in which the furin site, aa 164-167, RKKR, is changed to PGG. This PA cannot be proteolytically activated, so it cannot make an oligomer, is not internalized rapidly into cells, and cannot internalize LF and EF. This provides a useful negative control in many studies. This protein can still bind to the toxin receptors, and therefore acts as a competitive toxin inhibitor. This allows its use in Schild plot analyses to measure PA affinity for receptors.

Anthrax toxin is a three-protein exotoxin secreted by virulent strains of the bacterium, Bacillus anthracis, the causative agent of anthrax. Anthrax toxin is composed of a cell-binding protein, known as protective antigen (PA), and two enzyme components, called edema factor (EF) and lethal factor (LF). Anthrax is caused by B. anthracis, a spore-forming, Gram positive, rod-shaped bacterium. The lethality of the disease is caused by the bacterium's two principal virulence factors: the polyglutamic acid capsule, which is anti-phagocytic, and the tripartite protein toxin, called anthrax toxin.

From the laboratory of Stephen H. Leppla, PhD, National Institute of Allergy and Infectious Diseases/NIH.

Catalog Number Product DataSheet Size AVAILABILITY Price Qty
PA-U7 (Anthrax Protective Mutant Antigen (PA-U7))
100ug (7.47mg/mL) In stock
Regular Price:$306.00
On Sale:

In order to purchase this product, we require a Letter of Assurance form to be completed. Download form here: PDF Kerafast Letter of Assurance


Product Type: Protein
Name: Furin site, aa 164-176, RKKR, is changed to PGG
Alternative Name(s): PA-U7
Strain: Expressed in avirulent engineered B. anthracisstrain BH450
Format: Purified protein (liquid)
Purity: S200 Size Exclusion Chromatography
Buffer: 10 mM Tris-HCl pH 8 and 100 mM NaCl , 0.5 mM EDTA
Concentration: 7.47mg/mL
Storage: -80C
Shipped: Dry ice

From the laboratory of Stephen H. Leppla, PhD, National Institute of Allergy and Infectious Diseases/NIH.
  1. Leppla SH. Production and purification of anthrax toxin. Methods Enzymol. 1988;165:103-16.
  2. Liu, S., Bugge, T. H., and Leppla, S. H. (2001) Targeting of tumor cells by cell surface urokinase plasminogen activator-dependent anthrax toxin. J.Biol.Chem. 276, 17976-17984
  3. Chen, K. H., Liu, S., Bankston, L. A., Liddington, R. C., and Leppla, S. H. (2007) Selection of anthrax toxin protective antigen variants that discriminate between the cellular receptors TEM8 and CMG2 and achieve targeting of tumor cells. J.Biol.Chem. 282, 9834-9846

If you publish research with this product, please let us know so we can cite your paper.